| Date: | 2006-12-08 |
| Acquiring pharma company: | Protherics (UK) |
| Acquired biotech company: | Macromed (USA) |
| Amount: | $25 million |
| Terms of the agreement: | |
| Other: | Protherics' goal was to obtain OncoGel® (a controlled-release formulation of paclitaxel for local use), currently in phase IIa for the treatment of dysphagia in patients with oesophageal cancer. |
